NICE Pathways
Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject. Find out more about NICE Pathways.
NICE guidelines
Evidence-based recommendations on a range of health and care topics. Find out more about NICE guidelines
-
Pancreatic cancer in adults: diagnosis and management (NG85)
-
Suspected cancer: recognition and referral (NG12)
Quality standards
Statements covering priority areas for quality improvement (including ways to measure quality). Find out more about Quality standards.
Technology appraisal guidance
Assessments of the clinical and cost effectiveness of health technologies (most commonly medicines, but also medical devices, procedures and diagnostic techniques). Find out more about Technology appraisals guidance.
-
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)
-
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)
Interventional procedures guidance
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS. Find out more about Interventional procedures guidance.
-
Irreversible electroporation for treating pancreatic cancer (IPG579)
-
Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy (IPG274)
-
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma (IPG464)
-
Laparoscopic distal pancreatectomy (IPG204)
Medtech innovation briefings
Information on device and diagnostic technologies to help local decision-making. Find out more about Medtech innovation briefings (MIBs).
In development
-
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma
-
Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]
-
Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413
-
Pancreatic cancer
-
Pancreatic cancer - capecitabine [ID389]
-
Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]
-
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]
-
Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]
New guidance and advice
Guidance and advice added since November 2017
-
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma
-
Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413
-
Pancreatic cancer
-
Pancreatic cancer in adults: diagnosis and management (NG85)
Updated guidance and advice
Guidance and advice updated since November 2017